What is the clinical evidence from this study?

Study design: Review. Population: Bleeding associated with direct oral anticoagulants (DOACs). Intervention: DOAC reversal agents (idarucizumab, andexanet alfa).

What question did this study set out to answer?

This research aims to address the urgent need for effective reversal strategies for direct oral anticoagulants in emergency situations.

August 4, 2016Thrombosis and HaemostasisOpen Access

Managing reversal of direct oral anticoagulants in emergency situations

View Full Paper

Ask AI

Bookmark

Population

Patients receiving direct oral anticoagulants who experience emergency situations such as life-threatening…

Design

Guideline

Authors

HBHarry R. Büller AFAnna FalangaVascular Medicine WHWerner HackeUniversity of Minnesota

Discussion

Member takes

Implication

Institutions must implement standardized DOAC reversal protocols now; reinforces Level 1 guideline consensus for emergency care.

Key Points

This research aims to address the urgent need for effective reversal strategies for direct oral anticoagulants in emergency situations.
Report based on findings from the Anticoagulation Education Task Force meetings
Discussion among patient groups and professionals from multiple medical specialties
Focus on reversal agents for dabigatran and factor Xa inhibitors
Idarucizumab shown to be an effective reversal agent for dabigatran.
Recommendations provided for specific indications when reversal agents are necessary or beneficial.
Standardized protocols suggested for emergency departments to manage bleeding related to anticoagulation therapy.

Structured PICO

Population

Patients receiving direct oral anticoagulants (DOACs) who experience emergency situations such as life-threatening bleeding or require urgent interventions.

Intervention

DOAC reversal agents (idarucizumab, andexanet alfa, ciraparantag) and standardized institutional bleeding management protocols.

The advent of specific DOAC reversal agents necessitates the development of standardized, multidisciplinary institutional protocols for managing severe bleeding and urgent surgical emergencies.

Limitations

Lack of readily available point-of-care devices to rapidly determine DOAC exposure at the bedside
Further studies are needed to clarify the residual role of concentrated clotting factors and when redosing of idarucizumab may become necessary

Cite This Study

Büller et al. (2016) conducted a review in Bleeding associated with direct oral anticoagulants (DOACs). DOAC reversal agents (idarucizumab, andexanet alfa) was evaluated. Specific reversal agents for direct oral anticoagulants, such as idarucizumab and andexanet alfa, provide rapid reversal of anticoagulant effects in emergency situations, necessitating standardized institutional protocols.

synapsesocial.com/papers/6a21d1b9caef8a5f82c01043 https://doi.org/10.1160/th16-05-0363

Topics

Anticoagulation in AF

View Full Paper

Ask AI

Bookmark

Managing reversal of direct oral anticoagulants in emergency situations

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Topics

Managing reversal of direct oral anticoagulants in emergency situations

Discussion

Member takes

Implication

Key Points

Structured PICO

Limitations

Cite This Study

Also Consider

Topics

Also Consider